美女免费一级视频在线观看

    • <form id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></form>
      <address id=BiMYPaeIF><nobr id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></nobr></address>

      Sponsored by Doceree
      




      Gold
      




      Sanofi, Havas Lynx NY, Havas Health & You Spain and Havas Now   
      FeNomenal
      




      Asthma is one of the most common chronic diseases in the world, and someone dies from an asthma attack every 10 minutes. Yet inflammation, which leads to attacks, is something many patients — and even doctors — fail to understand adequately.
      




      Patients exhale into a device, and this innovation immediately translates inflammation markers into an asthma melody, creating a piece of animated artwork set to music,  demonstrating how much inflammation is currently in their lungs. Using custom data visualization and audio design, the FeNonemal experience allows patients to see and hear their own risk in a way that inspires them to act. Their raw scores are correlated to an algorithm of shapes, colors and sounds that turned the lung’s distress into a surround-sound sensory experience. As they watch their personal inflammation swirl and circle on the screen in intensifying colors and concentration, they get the first visual understanding they’ve ever had of the connection between inflammation and asthma symptoms.
      




      This innovation highlights the importance of FeNO for asthma control to doctors and patients. Although the FeNO test is simple and non-invasive, the test is not yet widely used. In this approach, patients confront what could be an alarming concept in a comforting, calming — and even inspiring — way. They can immerse themselves in their data, with 17% learning they are currently at risk for an asthma attack. They could also see their score mapped against others in their region.
      




      Initially piloted in Spain, FeNomenal has been implemented in four hospitals and nearly a dozen clinical settings on three continents and in four languages.
      




      




      Silver
      




      The MND Association, Amylyx Pharmaceuticals and Area 23   
      Mind’s Eye
      




      Many people living with motor neurone disease feel overlooked and underestimated because people often assume their mental and emotional states have declined along with their bodies. Mind’s Eye was designed to create an accessible AI-generative-art platform for people living with debilitating, degenerative conditions that severely impair movement and speech. The inclusive UX, designed explicitly for devices already used, removed input barriers and allowed people living with MND to generate images and express themselves, creating and sharing images regardless of their level of mobility impairment.
      




      Click here to view 2024 MM+M Award Winners.